Minute Insight: Theranica’s Wearable Earns Expanded FDA Clearance For Preventing Migraines
Executive Summary
Theranica’s expanded US FDA clearance allows the company to market its prescription-based wearable as both an acute and preventive treatment for migraine headaches.
You may also be interested in...
‘Training People To Be Healthier’: Digital Therapeutics Programmed For Growth
Experts foresee the digital therapeutics market growing to $6bn-$9bn by 2025, driven in part by tech-empowered consumers and patients looking for solutions to better manage their own health and conditions. For medtechs, collaborations with software-driven start-ups will be key to harnessing personalized data and differentiating themselves in the marketplace.
US Medicare Creates New Code For Theranica’s Headache Device
Medicare beneficiaries suffering from migraines will soon have access to an innovate drug-free treatment at the touch of their smartphones.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.